Effects of Triptorelin Pamoate in Children With Precocious Puberty - Follow up Study [clinicaltrials:NCT00909844] - Clinical Trials - bio2rdf

Bio2RDF identifier

NCT00909844

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT00909844

http://www.w3.org/2001/XMLSchema#string

identifiers.org URI

NCT00909844

acronym [clinicaltrials_vocabulary:acronym]

DECAPUB

http://www.w3.org/2001/XMLSchema#string

actual enrollment [clinicaltrials_vocabulary:actual-enrollment]

35

http://www.w3.org/2001/XMLSchema#integer

arm group [clinicaltrials_vocabulary:arm-group]

NCT00909844 arm group f6cbb2b02e08adaed5e1a829cfed3c13 [clinicaltrials_resource:NCT00909844/arm-group/f6cbb2b02e08adaed5e1a829cfed3c13]

authority [clinicaltrials_vocabulary:authority]

clinicaltrials_resource:f75c5a855582d3b6ab2bcdae185de445

brief summary [clinicaltrials_vocabulary:brief-summary]

The purpose of the prot ...... until the end of the study.

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

Effects of Triptorelin Pamoate in Children With Precocious Puberty - Follow up Study

http://www.w3.org/2001/XMLSchema#string

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

Proportion of children with a stabilization or regression of Tanner pubertal stage at the end of the study, as compared to the stage at study entry (M6 of the phase III study 2-54-52014-143) M12, M24, M36, M48 and final visit (if applicable) [clinicaltrials_resource:88bfa3e4d5ce3f5c0d2082ad2cda7f75]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

Proportion of children with a stabilization or regression of Tanner pubertal stage at the end of the study, as compared to the stage at study entry (M6 of the phase III study 2-54-52014-143) M12, M24, M36, M48 and final visit (if applicable) [clinicaltrials_resource:187f7e0e9e8d629746d38c10c742c264]

Proportion of children with a stabilization or regression of Tanner pubertal stage at the end of the study, as compared to the stage at study entry (M6 of the phase III study 2-54-52014-143) M12, M24, M36, M48 and final visit (if applicable) [clinicaltrials_resource:5bf162f0ca1772c3d82ac9588c186998]

Proportion of children with a stabilization or regression of Tanner pubertal stage at the end of the study, as compared to the stage at study entry (M6 of the phase III study 2-54-52014-143) M12, M24, M36, M48 and final visit (if applicable) [clinicaltrials_resource:5bf98f0f614fade137350d9ebdece0a9]

Proportion of children with a stabilization or regression of Tanner pubertal stage at the end of the study, as compared to the stage at study entry (M6 of the phase III study 2-54-52014-143) M12, M24, M36, M48 and final visit (if applicable) [clinicaltrials_resource:5c7c467f0931d143535eafb6f4187ce7]

Proportion of children with a stabilization or regression of Tanner pubertal stage at the end of the study, as compared to the stage at study entry (M6 of the phase III study 2-54-52014-143) M12, M24, M36, M48 and final visit (if applicable) [clinicaltrials_resource:77b9bc17f2b1286c486da05f19aef8da]

Proportion of children with a stabilization or regression of Tanner pubertal stage at the end of the study, as compared to the stage at study entry (M6 of the phase III study 2-54-52014-143) M12, M24, M36, M48 and final visit (if applicable) [clinicaltrials_resource:db2978c7cd18b9842eb5458cf52bd2a8]

Proportion of children with a stabilization or regression of Tanner pubertal stage at the end of the study, as compared to the stage at study entry (M6 of the phase III study 2-54-52014-143) M12, M24, M36, M48 and final visit (if applicable) [clinicaltrials_resource:fb8cec8e4b6b5127a781adb308503d67]

completion date [clinicaltrials_vocabulary:completion-date]

2015-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT00909844 [clinicaltrials_resource:5d6281e5f749e6286f518bef3897f1d1]

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2009-05-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

No

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

Triptorelin (I.N.N.) [clinicaltrials_resource:56917ebb211ac5988182ab57f6fbf865]

intervention browse [clinicaltrials_vocabulary:intervention-browse]

Triptorelin Pamoate [clinicaltrials_resource:6e316a4db067b268d37a683b7bc3220e]

is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]

No

http://www.w3.org/2001/XMLSchema#string

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2015-06-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

Ipsen [clinicaltrials_resource:72e24e8f01584e350155390bbce36547]

location [clinicaltrials_vocabulary:location]

Hôpital Hôtel Dieu (CHU) [clinicaltrials_resource:2e500c5088a39d538bef3d752c7cbd18]

nct id [clinicaltrials_vocabulary:nct-id]

NCT00909844

http://www.w3.org/2001/XMLSchema#string

number of arms [clinicaltrials_vocabulary:number-of-arms]

1

http://www.w3.org/2001/XMLSchema#integer

official title [clinicaltrials_vocabulary:official-title]

Follow-up of the Phase III, Mu ...... ildren With Precocious Puberty

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

2-54-52014-159

http://www.w3.org/2001/XMLSchema#string

overall official [clinicaltrials_vocabulary:overall-official]

Brigitte Palestro, MD [clinicaltrials_resource:fbe2c5d3ab3bc9b02f68f8bef5ff1d8b]

overall status [clinicaltrials_vocabulary:overall-status]

Active, not recruiting [clinicaltrials_resource:a6bc1606956390bcd6a391faced78809]

oversight [clinicaltrials_vocabulary:oversight]

France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis) [clinicaltrials_resource:be0f4cc39ce377ef03a505ef7fd7a9e1]

phase [clinicaltrials_vocabulary:phase]

Phase 3 [clinicaltrials_resource:8357418e2694434468870b487644532d]

primary completion date [clinicaltrials_vocabulary:primary-completion-date]

2015-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

responsible party [clinicaltrials_vocabulary:responsible-party]

[clinicaltrials_resource:dbd41868ee618d3e64daa1adf8c3a8a0]

secondary id [clinicaltrials_vocabulary:secondary-id]

2008-000565-39

http://www.w3.org/2001/XMLSchema#string

source [clinicaltrials_vocabulary:source]

Ipsen [clinicaltrials_resource:72e24e8f01584e350155390bbce36547]

start date [clinicaltrials_vocabulary:start-date]

2008-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT00909844 study design [clinicaltrials_resource:108121d86de596ee134bc8c0f8bb219c]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT00909844

verification date [clinicaltrials_vocabulary:verification-date]

2015-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT00909844

http://www.w3.org/2001/XMLSchema#string

title

Effects of Triptorelin Pamoate in Children With Precocious Puberty - Follow up Study

@en

inDataset

clinicaltrials_resource:bio2rdf.dataset.clinicaltrials.R3

type

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

label

Effects of Triptorelin Pamoate ...... y [clinicaltrials:NCT00909844]

@en